TG Therapeutics remains a "Strong Buy" as its drug BRIUMVI shows strong market momentum with 63% year-over-year sales growth in Q1. The company raised its 2026 BRIUMVI sales guidance to $885–$900 million, supported by successful Phase 3 trial results that may expand its label and competitive position in the RMS market. TG Therapeutics also benefits from a solid cash position, $500 million in non-dilutive capital, and an expanded share repurchase program, enhancing its financial strength and flexibility.
TG Therapeutics announced that its CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 3, 2026. The event will be webcast live on the company's website. TG Therapeutics is ...
TG Therapeutics announced positive Phase 3 ENHANCE trial results demonstrating that a single 600 mg infusion of BRIUMVI for relapsing multiple sclerosis (RMS) provides bioequivalent drug exposure compared to the current two-dose initiation regimen. T...
TG Therapeutics announced presentations of new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers meeting. Data from the ongoing ENABLE Phase 4 study show significant patient-repor...
